CR20200124A - Inhibidores macrocíclicos de mcl-1 y métodos de uso - Google Patents
Inhibidores macrocíclicos de mcl-1 y métodos de usoInfo
- Publication number
- CR20200124A CR20200124A CR20200124A CR20200124A CR20200124A CR 20200124 A CR20200124 A CR 20200124A CR 20200124 A CR20200124 A CR 20200124A CR 20200124 A CR20200124 A CR 20200124A CR 20200124 A CR20200124 A CR 20200124A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibitors
- methods
- mcl
- macrocyclic
- compounds
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102220480121 H/ACA ribonucleoprotein complex subunit DKC1_R10A_mutation Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente divulgación proporciona compuestos de la Fórmula (I), en donde A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X e Y tienen cualquiera de los valores definidos en la memoria descriptiva, y sales aceptables desde el punto de vista farmacéutico de estos, que son útiles como agentes en el tratamiento de enfermedades y afecciones, incluido el cáncer. También se proporcionan composiciones farmacéuticas que comprenden compuestos de la Fórmula (I).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545853P | 2017-08-15 | 2017-08-15 | |
| US201762555475P | 2017-09-07 | 2017-09-07 | |
| US201862692663P | 2018-06-30 | 2018-06-30 | |
| PCT/US2018/000180 WO2019035911A1 (en) | 2017-08-15 | 2018-08-15 | MACROCYCLIC INHIBITORS OF MCL-1 AND METHODS OF USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200124A true CR20200124A (es) | 2020-09-28 |
Family
ID=65362347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200124A CR20200124A (es) | 2017-08-15 | 2018-08-15 | Inhibidores macrocíclicos de mcl-1 y métodos de uso |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US10676485B2 (es) |
| EP (2) | EP3988555A1 (es) |
| JP (1) | JP2020531433A (es) |
| KR (1) | KR20200041942A (es) |
| CN (1) | CN111818917A (es) |
| AU (1) | AU2018316620A1 (es) |
| BR (1) | BR112020003180A2 (es) |
| CA (1) | CA3073112A1 (es) |
| CL (2) | CL2020000363A1 (es) |
| CO (1) | CO2020002678A2 (es) |
| CR (1) | CR20200124A (es) |
| EC (1) | ECSP20018703A (es) |
| IL (1) | IL272681A (es) |
| MX (1) | MX2020001717A (es) |
| PE (1) | PE20200837A1 (es) |
| PH (1) | PH12020500327A1 (es) |
| RU (1) | RU2020110517A (es) |
| SG (2) | SG11202001182QA (es) |
| TW (1) | TW201920194A (es) |
| UA (1) | UA126586C2 (es) |
| UY (1) | UY37843A (es) |
| WO (1) | WO2019035911A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111032045B (zh) | 2017-08-15 | 2023-08-15 | 安吉奥斯医药品有限公司 | 用于治疗血液病症的丙酮酸激酶激活剂 |
| EP3668502A4 (en) * | 2017-08-15 | 2021-01-13 | AbbVie Inc. | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE |
| CR20200124A (es) * | 2017-08-15 | 2020-09-28 | Abbvie Inc | Inhibidores macrocíclicos de mcl-1 y métodos de uso |
| US20190055264A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| MX2020002611A (es) | 2017-09-07 | 2020-07-13 | Univ Res Inst Inc Augusta | Activador especifico de akt3 y usos del mismo. |
| CA3138058A1 (en) | 2019-05-20 | 2020-11-26 | Matthew T. Burger | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| WO2022115451A1 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| JP7673255B2 (ja) | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| PE20251072A1 (es) | 2022-05-20 | 2025-04-10 | Novartis Ag | Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos |
| TW202540186A (zh) | 2023-11-22 | 2025-10-16 | 瑞士商諾華公司 | 抗ｃｄ７抗體藥物結合物及其使用方法 |
| PY24103486A (es) | 2023-11-22 | 2025-06-06 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| WO2025126157A1 (en) | 2023-12-15 | 2025-06-19 | Advesya | Anti-il-1rap binding domains and antibody-drug conjugates thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101667822B1 (ko) * | 2008-04-30 | 2016-10-19 | 내셔날 헬스 리서치 인스티튜트 | 오로라 키나아제 저해제용 접합 2고리 피리미딘 화합물 |
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JO3474B1 (ar) * | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| FR3037958B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037959B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037956B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3046792B1 (fr) | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| SMT202000249T1 (it) | 2016-04-22 | 2020-07-08 | Astrazeneca Ab | Inibitori di mcl1 macrociclici per il trattamento di cancro |
| WO2018015526A1 (en) | 2016-07-22 | 2018-01-25 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof |
| IL266198B2 (en) | 2016-10-28 | 2023-11-01 | Servier Lab | Liposomal formulation for use in cancer treatment |
| EP3567043B1 (en) | 2017-01-05 | 2023-12-06 | Henan Genuine Biotech Co., Ltd. | 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer |
| UY37560A (es) | 2017-01-06 | 2018-07-31 | Servier Lab | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta |
| US20190055264A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| CR20200124A (es) * | 2017-08-15 | 2020-09-28 | Abbvie Inc | Inhibidores macrocíclicos de mcl-1 y métodos de uso |
| EP3668502A4 (en) * | 2017-08-15 | 2021-01-13 | AbbVie Inc. | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE |
| CN107573360B (zh) | 2017-10-27 | 2019-08-09 | 都创(上海)医药科技有限公司 | 一种多靶点小分子化合物s63845的制备方法 |
-
2018
- 2018-08-15 CR CR20200124A patent/CR20200124A/es unknown
- 2018-08-15 CN CN201880066986.9A patent/CN111818917A/zh active Pending
- 2018-08-15 KR KR1020207007568A patent/KR20200041942A/ko not_active Ceased
- 2018-08-15 CA CA3073112A patent/CA3073112A1/en active Pending
- 2018-08-15 UY UY0001037843A patent/UY37843A/es not_active Application Discontinuation
- 2018-08-15 PE PE2020000240A patent/PE20200837A1/es unknown
- 2018-08-15 UA UAA202001749A patent/UA126586C2/uk unknown
- 2018-08-15 US US15/998,789 patent/US10676485B2/en active Active
- 2018-08-15 JP JP2020508463A patent/JP2020531433A/ja active Pending
- 2018-08-15 WO PCT/US2018/000180 patent/WO2019035911A1/en not_active Ceased
- 2018-08-15 SG SG11202001182QA patent/SG11202001182QA/en unknown
- 2018-08-15 AU AU2018316620A patent/AU2018316620A1/en not_active Abandoned
- 2018-08-15 MX MX2020001717A patent/MX2020001717A/es unknown
- 2018-08-15 BR BR112020003180-1A patent/BR112020003180A2/pt not_active IP Right Cessation
- 2018-08-15 RU RU2020110517A patent/RU2020110517A/ru unknown
- 2018-08-15 EP EP21197248.4A patent/EP3988555A1/en active Pending
- 2018-08-15 SG SG10202106345VA patent/SG10202106345VA/en unknown
- 2018-08-15 TW TW107128523A patent/TW201920194A/zh unknown
- 2018-08-15 EP EP18846737.7A patent/EP3652184A4/en not_active Withdrawn
-
2020
- 2020-02-12 CL CL2020000363A patent/CL2020000363A1/es unknown
- 2020-02-13 PH PH12020500327A patent/PH12020500327A1/en unknown
- 2020-02-14 IL IL272681A patent/IL272681A/en unknown
- 2020-03-10 CO CONC2020/0002678A patent/CO2020002678A2/es unknown
- 2020-03-13 EC ECSENADI202018703A patent/ECSP20018703A/es unknown
- 2020-05-11 US US16/872,279 patent/US20200325153A1/en not_active Abandoned
- 2020-11-12 CL CL2020002943A patent/CL2020002943A1/es unknown
-
2022
- 2022-02-03 US US17/649,906 patent/US20230183261A1/en not_active Abandoned
-
2024
- 2024-02-29 US US18/592,020 patent/US20250092062A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020001717A (es) | 2020-10-08 |
| US20250092062A1 (en) | 2025-03-20 |
| RU2020110517A3 (es) | 2022-03-23 |
| UA126586C2 (uk) | 2022-11-02 |
| JP2020531433A (ja) | 2020-11-05 |
| PE20200837A1 (es) | 2020-08-13 |
| AU2018316620A1 (en) | 2020-03-12 |
| KR20200041942A (ko) | 2020-04-22 |
| RU2020110517A (ru) | 2021-09-16 |
| SG11202001182QA (en) | 2020-03-30 |
| IL272681A (en) | 2020-03-31 |
| CA3073112A1 (en) | 2019-02-21 |
| EP3988555A1 (en) | 2022-04-27 |
| CL2020000363A1 (es) | 2020-06-12 |
| US20230183261A1 (en) | 2023-06-15 |
| EP3652184A1 (en) | 2020-05-20 |
| BR112020003180A2 (pt) | 2020-09-15 |
| US20200325153A1 (en) | 2020-10-15 |
| EP3652184A4 (en) | 2020-05-20 |
| ECSP20018703A (es) | 2020-04-22 |
| PH12020500327A1 (en) | 2020-10-12 |
| UY37843A (es) | 2019-03-29 |
| TW201920194A (zh) | 2019-06-01 |
| CO2020002678A2 (es) | 2020-08-10 |
| CN111818917A (zh) | 2020-10-23 |
| WO2019035911A1 (en) | 2019-02-21 |
| SG10202106345VA (en) | 2021-07-29 |
| US10676485B2 (en) | 2020-06-09 |
| US20190144465A1 (en) | 2019-05-16 |
| CL2020002943A1 (es) | 2021-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500327A1 (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| UY37842A (es) | Inhibidores de mcl-1 macrocíclicos y métodos de uso | |
| UY37844A (es) | Inhibidores de mcl-1 macrocíclicos y métodos de uso | |
| PH12018501920A1 (en) | Bromodomain inhibitors | |
| MX2015017963A (es) | Inhibidores de bromodominio. | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| MX2022010520A (es) | Macrociclos peptidicos contra acinetobacter baumannii. | |
| PH12015502004A1 (en) | Tetracyclic bromodomain inhibitors | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| MX2015012005A (es) | Inhibidores de bromodominio. | |
| MX2016007440A (es) | Inhibidores del bromodominio. | |
| MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
| UA118233C2 (uk) | Сполуки, які інгібують білок mcl-1 | |
| MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| PH12014501469A1 (en) | Bromodomain inhibitors | |
| PH12016501750B1 (en) | Human plasma kallikrein inhibitors | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX2019004375A (es) | Inhibidores de bromodominios. | |
| MX2019004187A (es) | Inhibidores de bromodominios. | |
| MX2017002627A (es) | Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak. | |
| MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
| MX2017002747A (es) | Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak. | |
| NZ780408A (en) | Human plasma kallikrein inhibitors |